Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
|Articles|March 1, 2013
3M Drug Delivery Systems Spring Show Guide
Advertisement
For pharmaceutical and biotech companies seeking innovation, quality and performance, 3M is the global expert in manufacturing from start-to-finish. See us at Interphex New York (April 23-25), booth # 2143, to find how trusted inhalation and transdermal drug delivery technologies from 3M can meet your product needs!
3M Drug Delivery Systems, St. Paul, MN |
Shows attending:
- PDA (Nov 5-6 in Switzerland) - (Booth 76)
- BIO (attending, but no booth)
- Interphex (Apr 23-25 NY) - Booth 2143
- AAPS Biotech (Nov 10-14 TX) - Booth 4023
- RDD (May 21-24 Berlin) - Booth TBD
- MD&ME June 18-20 - Booth 3511
- CRS (July 21-24 Hawaii - Booth 113
- PODD (Oct 10-11 Boston) - Booth TBD
- World Vaccine Congress (Oct 16-17) - Booth TBD
- DDS (Dec 11-13 Edinburgh, UK) - Booth TBD
Advertisement
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
2
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
3
PharmTech AI Pulse Check: Validating Multi-Agent Systems, OCR Models in GxP
4
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
5